Related Experiment Videos
TNF antagonist safety in rheumatoid arthritis: updated evidence from observational registries
Adeel Nasir1, Jeffrey D Greenberg
1Division of Rheumatology, NYU Hospital for Joint Diseases, and New York University School of Medicine, New York, NY 10003, USA.
Abstract:
Although the efficacy of tumor necrosis factor (TNF) antagonists for the treatment of rheumatoid arthritis (RA) has been established in randomized controlled trials (RCTs), safety concerns have emerged, particularly with regard to risk of infection, malignancy, and cardiovascular (CV) outcomes. Because of the shorter duration and limited number of patients enrolled in RCTs, evidence regarding the risk of rare adverse outcomes is frequently inconclusive. Longterm observational studies, as well as RCT meta-analyses, provide additional safety data. This review discusses the emerging evidence from observational registries on the risk of infection, malignancy, and CV outcomes associated with TNF antagonists.
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
Rheumatic Heart Disease III: Medical Management
The JAK-STAT Signaling Pathway
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies